New Objective FlowChip for Biomarker Discovery: Rafael Melani presents the Blood Proteoform Atlas at ASMS

June 9, 2022 – Littleton, MA (USA) New Objective, Inc., the global leader in innovative solutions for nanoflow and microflow LC-MS, is providing laboratories leading patient focused studies with a universal platform for robust, high-performance separations that deliver the reproducibility required for patient driven studies with limited sample volumes in the FlowChip. The FlowChip solution, a novel standard for Everyday use has fueled ongoing quantitative studies in The Kelleher Research Group at Northwestern University in the discovery of biomarker candidates in liver transplanted patients using Top-Down Proteomic LC-MS analysis.

Rafael Melani with The Kelleher Research Group presented his talk Blood Proteoform Atlas and the Discovery of Biomarker Candidates in Liver Transplanted Recipients using Proteoform-Reaction-Monitoring (PfRM) at the 70th ASMS Conference on Mass Spectrometry and Allied Topics in Minneapolis, Minnesota. The oral presentation on the afternoon of Thursday June 9^th shared recent work featuring the FlowChip as the standard solution for quantitative studies in liver transplant longitudinal samples.

Rafael’s presentation which shared the ongoing establishment of a Blood Proteoform Atlas as a reference map of proteoforms, building on the recent publication in Science, demonstrated improvements in the liver transplant immunoproteoform assay using Proteoform Reaction Monitoring, a Top-Down Proteomics approach developed at Northwestern. Improvements in sensitivity, specificity, and accuracy over the MS1 approach will enable the identification of biomarker candidates and understand graft rejection for liver transplant patients.

FlowChip, an integrated solution featuring the performance of PicoFrit, the industry standard for bottom-up proteomic analysis, is delivering, as Rafa has stated “excellent results”. Familiar with the performance of PicoFrit, Rafa together with colleagues at Northwestern readily recognized the value in the FlowChip for patient driven studies demanding reproducible results over time (longitudinal) as they launched the integration of FlowChip as a standard platform in March 2021 and featured in a November webinar hosted by New Objective.